Production (Stage)
Fulcrum Therapeutics, Inc.
FULC
$6.85
$0.071.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -510.00K | -9.73M | -17.91M | -20.23M | -99.43M |
| Total Depreciation and Amortization | 1.47M | 1.59M | 1.73M | 1.89M | 2.09M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.68M | 10.16M | 10.75M | 10.24M | 8.68M |
| Change in Net Operating Assets | -2.82M | -4.25M | -3.19M | -4.35M | -3.47M |
| Cash from Operations | 7.81M | -2.22M | -8.62M | -12.45M | -92.13M |
| Capital Expenditure | -250.00K | -278.00K | -124.00K | -170.00K | -365.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.43M | 32.51M | 48.45M | 63.16M | 95.74M |
| Cash from Investing | -6.68M | 32.23M | 48.32M | 62.99M | 95.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.10M | 2.75M | 2.95M | 2.32M | 2.08M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.10M | 2.75M | 2.95M | 2.32M | 2.08M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.23M | 32.76M | 42.66M | 52.86M | 5.32M |